Nuvo Research Provides Pennsaid® Update
MISSISSAUGA, ON, April 12, 2012 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today provided an update on U.S. developments relating to Pennsaid, its topical non-steroidal anti-inflammatory drug (NSAID) used to treat the signs and symptoms of osteoarthritis (OA) of the knee. Pennsaid U.S. Pennsaid is sold in the U.S.

Swank Capital and Cushing® MLP Asset Management Announce Rebalancing of the Cushing® MLP High Income Index
DALLAS, April 5, 2012 /PRNewswire/ -- Swank Capital, LLC and Cushing® MLP Asset Management, LP announced today that the 30 members of the Cushing® MLP High Income Index will be rebalanced after the market close on April 13, 2012 as part of normal index operations.

diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay
SOUTH SAN FRANCISCO, Calif., March 19, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a company focused on proprietary cardiovascular diagnostic products, today highlighted data from two recent studies evaluating the clinical utility of its PLAC® Test for Lp-PLA(2)  Activity.

diaDexus Launches PLAC® Test for Lp-PLA(2) Activity in Europe
SOUTH SAN FRANCISCO, March 5, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced the commercial launch of its CE-marked PLAC® Test for Lp-PLA(2) Activity in Europe.

Related News: